Company Monitoring Page for Biogen

latest headlines for company on cafepharma

With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda
Endpoints
Fri, 02/11/22 - 10:11 am
Tags:
Biogen, Vir Biotechnology, GSK, Johanna Friedl-Naderer, Takeda, PhRMA
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Tags:
Eisai, Biogen, Aduhelm, Alzheimer's disease, FDA, CMS
Backing Biogen, 75+ House Republicans call on CMS to abandon its decision to limit amyloid-targeted Alzheimer's drugs to trials
Endpoints
Wed, 02/9/22 - 10:53 pm
Tags:
Biogen, Aduhelm, CMS, Alzheimer's disease
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
Reuters
Mon, 02/7/22 - 11:26 pm
Tags:
Biogen, Aduhelm, FTC, SEC, Alzheimer's disease
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year
Fierce Pharma
Thu, 02/3/22 - 11:45 am
Tags:
Biogen, earnings, Aduhelm, Alzheimer's disease
Biogen buys into fast-advancing Roche cancer drug
BioPharma Dive
Tue, 02/1/22 - 11:30 pm
Tags:
Biogen, Roche, lymphoma, cancer
CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say
Fierce Pharma
Tue, 02/1/22 - 10:50 am
Tags:
CMS, Biogen, Aduhelm, Eli Lilly, Roche, Alzheimer's disease
Biogen promises increased diversity in Phase 4 Aduhelm trial
Biopharma Reporter
Tue, 02/1/22 - 10:41 am
Tags:
Biogen, Aduhelm, clinical trials, clinical trial diversity
Two Biogen board members depart as company struggles to get Aduhelm off the ground
Fierce Pharma
Mon, 01/31/22 - 11:49 pm
Tags:
Biogen, Aduhelm
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Biopharma Reporter
Fri, 01/28/22 - 10:07 am
Tags:
Biogen, biosimilars, Samsung Bioepis
Scott Gottlieb criticizes CMS in feud over Aduhelm coverage, calls out their lack of expertise
Endpoints
Thu, 01/27/22 - 11:41 pm
Tags:
Biogen, Aduhelm, CMS, Scott Gottlieb
Under pressure, Biogen outlines ambitious diversity goals for Aduhelm study — but the Medicare fight is still on
Endpoints
Thu, 01/27/22 - 10:58 am
Tags:
Biogen, Alzheimer's disease, clinical trials, clinical trial diversity, Aduhelm
A senior Biogen commercial exec exits Alzheimer's unit amid exodus as Aduhelm woes mount
Endpoints
Thu, 01/27/22 - 10:42 am
Tags:
Biogen, Alzheimer's disease, Aduhelm
Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelm
Fierce Biotech
Fri, 01/21/22 - 11:13 am
Tags:
Eli Lilly, Biogen, Alzheimer's disease, Aduhelm, donanemab, clinical trials, David Ricks
Where Will Biogen Be in 5 Years?
Motley Fool
Sun, 01/16/22 - 03:56 am
Tags:
Biogen, Aduhelm, zuranolone, BIIB115, lecanemab
Biogen compiles buyout target list as Aduhelm woe deepens: Stat
Fierce Pharma
Fri, 01/14/22 - 01:19 pm
Tags:
Biogen, Aduhelm, M&A
Biotech investors pray for a takeover miracle
EP Vantage
Fri, 01/14/22 - 11:09 am
Tags:
M&A, biotech, Amylyx Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Aurinia Pharmaceuticals, Biogen, Biohaven, Bristol Myers Squibb, Eli Lilly, GSK, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi
With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment
Stat
Fri, 01/14/22 - 10:56 am
Tags:
Medicare, Aduhelm, Biogen, CMS, racial disparity, Alzheimer's disease
Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years
Endpoints
Thu, 01/13/22 - 10:26 pm
Tags:
Biogen, Aduhelm, CMS, drug reps, Medicare, Alzheimer's disease
7 drugs likely to hit $1B in annual revenue in the next 5 years
Beckers Hospital Review
Thu, 01/13/22 - 07:31 am
Tags:
FDA, adagrasib, donanemab, faricimab, lecanemab, tezepelumab, tirzepatide, vutrisiran, Eli Lilly, Mirati Therapeutics, Roche, Chugai, Eisai, Biogen, AstraZeneca, Amgen, Alnylam

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.